{
    "nct_id": "NCT03634540",
    "official_title": "A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",
    "inclusion_criteria": "* Has locally advanced or metastatic RCC with predominantly clear cell subtype\n* Has at least one measurable lesion as defined by RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Has adequate organ function defined as follows:\n\n  * Absolute neutrophil count ≥ 1,000/µL, hemoglobin level ≥ 10 g/dL and platelet count ≥ 100,000/µL without transfusion or growth factor support within 2 weeks prior to obtaining the hematology values at screening;\n  * Serum creatinine level ≤ 2.0 × upper limit of normal (ULN)\n  * Transaminase levels (AST/ALT) ≤ 3.0 × upper limit of normal (ULN); total bilirubin (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease *Cohort 1: Participants must not have received prior systemic therapy for advanced or metastatic ccRCC\n* Cohort 2: Participants must have received prior immunotherapy and no more than two prior treatments for advanced or metastatic ccRCC\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received prior treatment with belzutifan or other HIF2α inhibitors\n* Has received prior treatment with cabozantinib\n* Has had radiation therapy for bone metastases within two weeks of starting study drug\n* Has a history of untreated brain metastases or history of leptomeningeal disease or spinal cord compression\n* Has failed to recover from the reversible effects of prior anticancer therapy\n* Has uncontrolled or poorly controlled hypertension\n* Is receiving anticoagulant therapy\n* Has had any major cardiovascular event within 6 months prior to study drug administration\n* Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results\n* Has had major surgery within 3 months before first study drug administration\n* Has an active infection requiring systemic treatment\n* Is participating in another therapeutic clinical trial",
    "miscellaneous_criteria": ""
}